Severe Intoxication with Methotrexate Possibly Associated with Concomitant Use of Proton Pump Inhibitors

• Published in: Anticancer research 2010-03, Vol.30 (3), p.963-965
• Main Authors: SANTUCCI, Raoul, LEVEQUE, Dominique, KEMMEL, Véronique, LUTZ, Patrick, GEROUT, Anne-Cécile, N'GUYEN, Aurélia, LESCOUTE, Aurélie, SCHNEIDER, Francis, BERGERAT, Jean-Pierre, HERBRECHT, Raoul
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Aged; Antimetabolites, Antineoplastic - administration & dosage; Antimetabolites, Antineoplastic - pharmacokinetics; Antimetabolites, Antineoplastic - poisoning; Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Benzimidazoles - administration & dosage; Benzimidazoles - pharmacology; Biological and medical sciences; Bone Neoplasms - drug therapy; Bone Neoplasms - metabolism; Child; Child, Preschool; Drug Interactions; gamma-Glutamyl Hydrolase - therapeutic use; Humans; Lymphoma - drug therapy; Lymphoma - metabolism; Medical sciences; Methotrexate - administration & dosage; Methotrexate - pharmacokinetics; Methotrexate - poisoning; Middle Aged; Neuroblastoma - drug therapy; Neuroblastoma - metabolism; Osteosarcoma - drug therapy; Osteosarcoma - metabolism; Proton Pump Inhibitors - administration & dosage; Proton Pump Inhibitors - pharmacology; Retrospective Studies; Tumors; Young Adult
• ISSN: 0250-7005; 1791-7530

Delayed elimination of methotrexate associated with serious side-effects has been attributed to the co-administration of benzimidazole proton pump inhibitors. We have retrospectively analyzed the causes of delayed methotrexate elimination in patients who had received the rescue agent glucarpidase to evaluate the potential implication of benzimidazoles. Between 2002 and 2008, six patients (mean age: 30 years; range: 4-74 years) were treated with glucarpidase. Delayed elimination associated with impaired renal function occured after the first cycle except in 2 patients (2nd and 8th administration of high-dose methotrexate). The possible causes of delayed elimination identified were: insufficient hydration (n=1) and drug-drug interactions (n=5). The potential drug-drug interactions included the co-administration of piperacillin/tazobactam (n=1) and proton pump inhibitors (omeprazole, n=3; esomeprazole, n=2). Impaired elimination of methotrexate was not observed either in the 3 patients who were treated further or during the previous cycles of the 2 pretreated patients in relation to the absence of co-prescription of proton pump inhibitors. In line with the recent literature and given the prohibitive cost of glucarpidase, we have advocated the cessation of proton pump inhibitors administration during methotrexate treatment.